Literature DB >> 3702930

Renal histopathologic alterations in patients treated with cyclosporine for uveitis.

A G Palestine, H A Austin, J E Balow, T T Antonovych, S G Sabnis, H G Preuss, R B Nussenblatt.   

Abstract

To evaluate abnormalities of renal morphology associated with long-term cyclosporine therapy, we obtained percutaneous renal biopsy specimens from 17 patients who had been treated for autoimmune uveitis with cyclosporine for an average of two years. For comparison, we also analyzed renal biopsy specimens from patients with idiopathic hematuria who had not received cyclosporine. The atrophic and sclerosing glomerular and tubulointerstitial lesions in the specimens were assessed to derive a chronicity index. The specimens from the patients treated with cyclosporine showed a significantly higher chronicity index than those from the controls (P less than 0.00005). All patients who had received cyclosporine had interstitial fibrosis, tubular atrophy, or both. A good functional predictor of the abnormalities in renal morphology was the length of time that a patient's serum creatinine had exceeded the base-line value by more than 50 percent. Chronic pathologic alterations were seen even in patients who had normal renal function at the time of the biopsy. In conjunction with sequential measurements of renal function, renal biopsy may have an important role in defining the type and degree of nephrotoxicity that can develop in patients receiving long-term cyclosporine therapy for autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3702930     DOI: 10.1056/NEJM198605153142005

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

Review 1.  Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity.

Authors:  P A Keown
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 2.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease.

Authors:  H H Tessler; T Jennings
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

4.  Drug-combination therapy of rheumatoid arthritis.

Authors:  P A Miescher; H Favre; R Lemoine; P Tamagnini
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Cyclosporine-induced nephrotoxicity in deoxycorticosterone-NaCl treated rats.

Authors:  J M Wyss; M S Mozaffari; P L St John; D R Abrahamson
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

6.  Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A.

Authors:  T A McCulloch; S J Harper; P K Donnelly; J Moorhouse; P R Bell; J Walls; J Feehally; P N Furness
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

7.  Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy.

Authors:  P A Miescher; H Favre; F Chatelanat; M J Mihatsch
Journal:  Klin Wochenschr       Date:  1987-08-03

8.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

9.  Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy.

Authors:  S J Hodgkinson; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

10.  Cyclosporin reduces renal prostanoid excretion in type 1 diabetic patients.

Authors:  V A Koivisto; M Leirisalo-Repo; R Pelkonen; U Turunen; J Rapola; L Viinikka; O Ylikorkala
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.